Seeking Alpha

NeoStem obtains 2 EU patents for ischemia program

  • NeoStem (NBS) has received the first two European patents for its CD34 Cell program, in which the company is developing treatments for ischemia, when the supply of oxygenated blood in the body is restricted.
  • The IP is for "Compositions and Methods of Vascular Injury Repair."
  • The CD34 program now has 16 granted and allowed patents around the world. (PR)
Comments (1)
  • JT06
    , contributor
    Comments (4) | Send Message
     
    Anyone have a price target on NBS?
    20 May, 02:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector